GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
- Saturday, September 28, 2019, 2:13
- PR Newswire
- Add a comment
LONDON, Sept. 28, 2019 /PRNewswire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announced GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody designed to selectively enhance T cell function, showed promising anti-tumour activity in combination with pembrolizumab in…
About the Author
admin has written 20652 stories on this site.